HBP Unit, General Surgery Department, Joan XXIII University Hospital, 43005 Tarragona, Spain.
Medicine and Surgery Department, Rovira i Virgili University, 43204 Reus, Spain.
Int J Mol Sci. 2024 Jan 29;25(3):1640. doi: 10.3390/ijms25031640.
Pancreatic ductal adenocarcinoma contributes significantly to global cancer-related deaths, featuring only a 10% survival rate over five years. The quest for novel tumor markers is critical to facilitate early diagnosis and tailor treatment strategies for this disease, which is key to improving patient outcomes. In pancreatic ductal adenocarcinoma, these markers have been demonstrated to play a crucial role in early identification, continuous monitoring, and prediction of its prognosis and have led to better patient outcomes. Nowadays, biopsy specimens serve to ascertain diagnosis and determine tumor type. However, liquid biopsies present distinct advantages over conventional biopsy techniques. They offer a noninvasive, easily administered procedure, delivering insights into the tumor's status and facilitating real-time monitoring. Liquid biopsies encompass a variety of elements, such as circulating tumor cells, circulating tumor DNA, extracellular vesicles, microRNAs, circulating RNA, tumor platelets, and tumor endothelial cells. This review aims to provide an overview of the clinical applications of liquid biopsy as a technique in the management of pancreatic cancer.
胰腺导管腺癌是导致全球癌症相关死亡的主要原因，其五年生存率仅为 10%。因此，寻找新的肿瘤标志物对于促进早期诊断和制定针对这种疾病的治疗策略至关重要，这是改善患者预后的关键。在胰腺导管腺癌中，这些标志物已被证明在早期识别、持续监测和预测其预后方面发挥着重要作用，并导致了更好的患者结局。目前，活检标本可用于确定诊断并确定肿瘤类型。然而，液体活检相对于传统的活检技术具有明显的优势。它们提供了一种非侵入性、易于管理的程序，可以深入了解肿瘤的状态，并实现实时监测。液体活检包括多种元素，如循环肿瘤细胞、循环肿瘤 DNA、细胞外囊泡、microRNAs、循环 RNA、肿瘤血小板和肿瘤内皮细胞。本综述旨在概述液体活检作为一种技术在胰腺癌管理中的临床应用。
